An Open-label, Crossover Study to Investigate the Potential Pharmacodynamic and Potential Pharmacokinetic Interaction Between Glyburide and GK Activator(2) in Type 2 Diabetes Patients Inadequately Controlled With Glyburide as Standard Prescribed Therapy.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Piragliatin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 01 Nov 2016 Results published in the Clinical Pharmacology in Drug Development
- 17 Jul 2007 Status changed from recruiting to completed.
- 02 Dec 2006 New trial record.